Advertisement

The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course

  • Rebecca Kuepper
  • Mette Skinbjerg
  • Anissa Abi-DarghamEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 212)

Abstract

Schizophrenia has long been associated with an imbalance in dopamine (DA) neurotransmission, and brain imaging has played an important role in advancing our knowledge and providing evidence for the dopaminergic abnormalities. This chapter reviews the evidence for DA dysfunction in different brain regions in schizophrenia, in particular striatal, extrastriatal, and prefrontal regions, with emphasis on recently published findings. As opposed to the traditional view that most striatal dopaminergic excess, associated with the positive symptoms of schizophrenia, involves the dopaminergic mesolimbic pathway, recent evidence points to the nigrostriatal pathway as the area of highest dysregulation. Furthermore, evidence from translational research suggests that dopaminergic excess may be present in the prodromal phase, and may by itself, as suggested by the phenotype observed in transgenic mice with developmental overexpression of dorso-striatal D2 receptors, be an early pathogenic condition, leading to irreversible cortical dysfunction.

Keywords

Schizophrenia Psychosis Dopamine dysfunction Neurochemical imaging 

References

  1. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 7(Suppl 1):S1–5Google Scholar
  2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767PubMedGoogle Scholar
  3. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci 97:8104–8109PubMedGoogle Scholar
  4. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708–3719PubMedGoogle Scholar
  5. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O’Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ (2004) Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55:1001–1006PubMedGoogle Scholar
  6. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65:1091–1093PubMedGoogle Scholar
  7. Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M. J Psychopharmacol. 2012 Jun;26(6):794-805. Epub 2011 Jul 18Google Scholar
  8. Abler B, Walter H, Erk S, Kammerer H, Spitzer M (2006) Prediction error as a linear function of reward probability is coded in human nucleus accumbens. Neuroimage 31:790–795PubMedGoogle Scholar
  9. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA (2000) Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47:361–370PubMedGoogle Scholar
  10. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Author, Washington, DCGoogle Scholar
  11. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, Takano H, Yasuno F, Kato M, Okubo Y, Suhara T (2009) Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 43:1219–1223PubMedGoogle Scholar
  12. Arnsten AF (2007) Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 17(Suppl 1):i6–15PubMedGoogle Scholar
  13. Arnsten AF (2011) Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci 29(3):215–23PubMedGoogle Scholar
  14. Bayer HM, Glimcher PW (2005) Midbrain dopamine neurons encode a quantitative reward prediction error signal. Neuron 47:129–141PubMedGoogle Scholar
  15. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309–369PubMedGoogle Scholar
  16. Bilder RM, Volavka J, Lachman HM, Grace AA (2004) The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29:1943–1961PubMedGoogle Scholar
  17. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569–2574PubMedGoogle Scholar
  18. Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, Malischke LM, DeJesus OT, Nickles RJ (1999) FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53:1212–1218PubMedGoogle Scholar
  19. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85:232–244PubMedGoogle Scholar
  20. Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328PubMedGoogle Scholar
  21. Carlsson A (1977) Does dopamine play a role in schizophrenia? Psychol Med 7:583–597PubMedGoogle Scholar
  22. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165–173PubMedGoogle Scholar
  23. Creese I, Burt DR, Snyder SH, Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483PubMedGoogle Scholar
  24. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ, Innis RB (2008) Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 163:171–182PubMedGoogle Scholar
  25. Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74:122–124PubMedGoogle Scholar
  26. Cumming P, Gjedde A (1998) Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29:37–61PubMedGoogle Scholar
  27. D’Ardenne K, McClure SM, Nystrom LE, Cohen JD (2008) BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. Science 319:1264–1267PubMedGoogle Scholar
  28. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167–174PubMedGoogle Scholar
  29. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486PubMedGoogle Scholar
  30. Deutch AY (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm 36:61–89Google Scholar
  31. Drew MR, Simpson EH, Kellendonk C, Herzberg WG, Lipatova O, Fairhurst S, Kandel ER, Malapani C, Balsam PD (2007) Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J Neurosci 27:7731–7739PubMedGoogle Scholar
  32. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M (2007) In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9:117–125PubMedGoogle Scholar
  33. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1–11PubMedGoogle Scholar
  34. Erritzoe D, Talbot P, Frankle WG, Abi-Dargham A (2003) Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clin North Am 13:817–832Google Scholar
  35. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544PubMedGoogle Scholar
  36. Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB (2000) Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl) 149:1–5Google Scholar
  37. Floresco SB, West AR, Ash B, Moore H, Grace AA (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968–973PubMedGoogle Scholar
  38. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK (2010) Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67:683–691PubMedGoogle Scholar
  39. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P (2011) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16:67–75PubMedGoogle Scholar
  40. Galineau L, Wilson AA, Garcia A, Houle S, Kapur S, Ginovart N (2006) In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse 60:172–183PubMedGoogle Scholar
  41. Garnett ES, Firnau G, Chan PK, Sood S, Belbeck LW (1978) [18F]fluoro-dopa, an analogue of DOPA, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 75:464–467PubMedGoogle Scholar
  42. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137–138PubMedGoogle Scholar
  43. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA (2006) Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97:1089–1103PubMedGoogle Scholar
  44. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S (2009) D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 34:662–671PubMedGoogle Scholar
  45. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baare W, Hemmingsen R, Videbaek C (2006) Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60:621–629PubMedGoogle Scholar
  46. Goldman-Rakic PS (1999) The “psychic” neuron of the cerebral cortex. Ann N Y Acad Sci 868:13–26PubMedGoogle Scholar
  47. Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437–458PubMedGoogle Scholar
  48. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3–16PubMedGoogle Scholar
  49. Goto Y, Otani S, Grace AA (2007) The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53:583–587PubMedGoogle Scholar
  50. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24PubMedGoogle Scholar
  51. Grace AA (1995) The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 37:111–129PubMedGoogle Scholar
  52. Grace AA (2012) Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 62:1342–1348PubMedGoogle Scholar
  53. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S (2008) Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29:400–410PubMedGoogle Scholar
  54. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S (2009) The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078–1086PubMedGoogle Scholar
  55. Griffon N, Sokoloff P, Diaz J, Levesque D, Sautel F, Schwartz JC, Simon P, Costentin J, Garrido F, Mann A et al (1995) The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Eur Neuropsychopharmacol 5(Suppl):3–9PubMedGoogle Scholar
  56. Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A (2003) Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28:1703–1711PubMedGoogle Scholar
  57. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54:225–232PubMedGoogle Scholar
  58. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245–256PubMedGoogle Scholar
  59. Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 174:151–162PubMedGoogle Scholar
  60. Hess EJ, Bracha HS, Kleinman JE, Creese I (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sci 40:1487–1497PubMedGoogle Scholar
  61. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U et al (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130–1131PubMedGoogle Scholar
  62. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41–50PubMedGoogle Scholar
  63. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Hietala J, Cannon TD (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62:371–378PubMedGoogle Scholar
  64. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Cannon TD, Hietala J (2006) Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 163:1747–1753PubMedGoogle Scholar
  65. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 35:549–562PubMedGoogle Scholar
  66. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13–20PubMedGoogle Scholar
  67. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P (2011a) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 16:885–886PubMedGoogle Scholar
  68. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P (2011c) Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168(12):1311–17PubMedGoogle Scholar
  69. Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC (2003) Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 65:39–46PubMedGoogle Scholar
  70. Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J (2008) Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 63:114–117PubMedGoogle Scholar
  71. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S (2008) The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 33:473–479PubMedGoogle Scholar
  72. Joyce JN, Lexow N, Bird E, Winokur A (1988) Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 2:546–557PubMedGoogle Scholar
  73. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29:409–416PubMedGoogle Scholar
  74. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081–1090PubMedGoogle Scholar
  75. Kapur S, Remington G (2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873–883PubMedGoogle Scholar
  76. Kapur S, Mizrahi R, Li M (2005) From dopamine to salience to psychosis–linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79:59–68PubMedGoogle Scholar
  77. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761–767PubMedGoogle Scholar
  78. Kashihara K, Sato M, Fujiwara Y, Harada T, Ogawa T, Otsuki S (1986) Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Biol Psychiatry 21:650–656PubMedGoogle Scholar
  79. Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum RL, Mann JJ, Laruelle M (1999) Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302–308PubMedGoogle Scholar
  80. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, Suckow RF, Van Heertum RL, Laruelle M (2002) NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse 43:19–29PubMedGoogle Scholar
  81. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010a) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239PubMedGoogle Scholar
  82. Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A (2010b) Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 68:634–641PubMedGoogle Scholar
  83. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, Moore H, Kandel ER (2006) Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49:603–615PubMedGoogle Scholar
  84. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024–1031PubMedGoogle Scholar
  85. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355–371PubMedGoogle Scholar
  86. Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol (Oxford, England) 11:123–131Google Scholar
  87. Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, Kleinman JE (1994) Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 36:827–835PubMedGoogle Scholar
  88. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269–271PubMedGoogle Scholar
  89. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115–120PubMedGoogle Scholar
  90. Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA (1996) D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 7:1945–1948PubMedGoogle Scholar
  91. Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR, Tamminga CA (1998) Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study. Mol Psychiatry 3:528–533PubMedGoogle Scholar
  92. Laruelle M (1998) Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med 42:211–221PubMedGoogle Scholar
  93. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451PubMedGoogle Scholar
  94. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF et al (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182–1190PubMedGoogle Scholar
  95. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235–9240PubMedGoogle Scholar
  96. Laruelle M, D’Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162–174PubMedGoogle Scholar
  97. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56–72PubMedGoogle Scholar
  98. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R (2000) Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47:371–379PubMedGoogle Scholar
  99. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138–158PubMedGoogle Scholar
  100. Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA (2001) Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 47:59–67PubMedGoogle Scholar
  101. Lewis DA, Gonzalez-Burgos G (2000) Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res Bull 52:309–317PubMedGoogle Scholar
  102. Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205–229PubMedGoogle Scholar
  103. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681–688PubMedGoogle Scholar
  104. Lisman J (2012) Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Curr Opin Neurobiol. 2012 Jun;22(3):537–544Google Scholar
  105. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234–242PubMedGoogle Scholar
  106. Lodge DJ, Grace AA (2008) Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox Res 14:97–104PubMedGoogle Scholar
  107. Lynch MR (1992) Schizophrenia and the D1 receptor: focus on negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 16:797–832PubMedGoogle Scholar
  108. Marzella PL, Hill C, Keks N, Singh B, Copolov D (1997) The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia. Biol Psychiatry 42:648–654PubMedGoogle Scholar
  109. Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M (2005) Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181:401–406PubMedGoogle Scholar
  110. Mateos JJ, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M (2007) Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 191:805–811PubMedGoogle Scholar
  111. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134–142PubMedGoogle Scholar
  112. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267–271PubMedGoogle Scholar
  113. Meyer-Lindenberg A, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, Berman KF (2005) Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 62:379–386PubMedGoogle Scholar
  114. Mizrahi R (2010) Advances in PET analyses of stress and dopamine. Neuropsychopharmacology 35:348–349PubMedGoogle Scholar
  115. Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881–884PubMedGoogle Scholar
  116. Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15:2186–2191PubMedGoogle Scholar
  117. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162:2352–2359PubMedGoogle Scholar
  118. Nobrega JN, Seeman P (1994) Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO. Synapse 17:167–172PubMedGoogle Scholar
  119. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Fujimura Y, Matsumoto R, Ota M, Takano A, Otsuka A, Yasuno F, Okubo Y, Kashima H, Suhara T (2009) Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 108:78–84PubMedGoogle Scholar
  120. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634–636PubMedGoogle Scholar
  121. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD (2006) Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442:1042–1045PubMedGoogle Scholar
  122. Pimoule C, Schoemaker H, Reynolds GP, Langer SZ (1985) [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson’s disease. Eur J Pharmacol 114:235–237PubMedGoogle Scholar
  123. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91:11651–11654PubMedGoogle Scholar
  124. Reynolds GP, Czudek C (1988) Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacol Bull 24:345–347PubMedGoogle Scholar
  125. Reynolds GP, Mason SL (1994) Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 63:1576–1577PubMedGoogle Scholar
  126. Schmitt GJ, Meisenzahl EM, Frodl T, La Fougere C, Hahn K, Möller HJ, Dresel S (2005) The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J Psychopharmacol 19:488–493PubMedGoogle Scholar
  127. Schmitt GJ, Frodl T, Dresel S, la Fougere C, Bottlender R, Koutsouleris N, Hahn K, Möller HJ, Meisenzahl EM (2006) Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256:115–121PubMedGoogle Scholar
  128. Schmitt GJ, la Fougere C, Dresel S, Frodl T, Hahn K, Möller HJ, Meisenzahl EM (2008) Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naive schizophrenic patients. Schizophr Res 101:133–141PubMedGoogle Scholar
  129. Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, Small SA (2009) Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66:938–946PubMedGoogle Scholar
  130. Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1–27PubMedGoogle Scholar
  131. Seeman P (2010) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 receptors. CNS Neurosci Ther 9(7):777–89Google Scholar
  132. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology 1:5–15PubMedGoogle Scholar
  133. Seeman P, Guan HC, Van Tol HH (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365:441–445PubMedGoogle Scholar
  134. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O’Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102:3513–3518PubMedGoogle Scholar
  135. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60:319–346PubMedGoogle Scholar
  136. Shotbolt P, Stokes PR, Owens SF, Toulopoulou T, Picchioni MM, Bose SK, Murray RM, Howes OD (2011) Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 41:1–8Google Scholar
  137. Sibley DR, De Lean A, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351–6361PubMedGoogle Scholar
  138. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174–180Google Scholar
  139. Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585–596PubMedGoogle Scholar
  140. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A (2007) [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27:1733–1741PubMedGoogle Scholar
  141. Smith A, Li M, Becker S, Kapur S (2006) Dopamine, prediction error and associative learning: a model-based account. Network (Bristol, England) 17:61–84Google Scholar
  142. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25–43PubMedGoogle Scholar
  143. Soliman A, O’Driscoll GA, Pruessner J, Holahan AL, Boileau I, Gagnon D, Dagher A (2007) Stress-induced dopamine release in humans at risk of psychosis: a [(11)C]Raclopride PET Study. Neuropsychopharmacology 33:2033–2041PubMedGoogle Scholar
  144. Stuber GD, Klanker M, de Ridder B, Bowers MS, Joosten RN, Feenstra MG, Bonci A (2008) Reward-predictive cues enhance excitatory synaptic strength onto midbrain dopamine neurons. Science 321:1690–1692PubMedGoogle Scholar
  145. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25–30PubMedGoogle Scholar
  146. Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY (1995) Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 681:109–116PubMedGoogle Scholar
  147. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 6:361–370Google Scholar
  148. Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165–173PubMedGoogle Scholar
  149. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J (2003) Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8:453–455PubMedGoogle Scholar
  150. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, Husso M, Tiihonen J (2006) Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256:382–387PubMedGoogle Scholar
  151. van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492–494PubMedGoogle Scholar
  152. Ward RD, Kellendonk C, Simpson EH, Lipatova O, Drew MR, Fairhurst S, Kandel ER, Balsam PD (2009) Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. Behav Neurosci 123:720–730PubMedGoogle Scholar
  153. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669PubMedGoogle Scholar
  154. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA (2006) High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry 59:389–394PubMedGoogle Scholar
  155. Woodward ND, Cowan RL, Park S, Ansari MS, Baldwin RM, Li R, Doop M, Kessler RM, Zald DH (2010) Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am J Psychiatry 168(4):418–26PubMedGoogle Scholar
  156. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH (2004) Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161:1496–1498PubMedGoogle Scholar
  157. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Takano A, Nakayama K, Halldin C, Farde L (2004) Low dopamine D(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161:1016–1022PubMedGoogle Scholar
  158. Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A (2004) Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71:371–375PubMedGoogle Scholar
  159. Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201–206PubMedGoogle Scholar
  160. Zhang ZJ, Reynolds GP (2002) A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 55:1–10PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Rebecca Kuepper
    • 1
  • Mette Skinbjerg
    • 2
  • Anissa Abi-Dargham
    • 2
    Email author
  1. 1.Department of Psychiatry and PsychologySouth Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical CenterMaastrichtThe Netherlands
  2. 2.Department of PsychiatryColumbia College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia UniversityNew YorkUSA

Personalised recommendations